LabStyle Innovations To Hold Investor Update Conference Call On Thursday, April 17, 2014

Published: Apr 11, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAESAREA, Israel, April 10, 2014 /PRNewswire/ -- LabStyle Innovations Corp. (OTCQB:DRIO), developer of the Dario Diabetes Management Solution, announces that its president and chief executive officer, Mr. Erez Raphael, and its Chief Financial Officer, Mr. Gadi Levin, will host a conference call at 10 am Eastern Time on Thursday April 17, 2014 to report positive developments of the company's recent commercial launch of Dario in selected jurisdictions as well as an update on the company's commercial and regulatory plans for Dario for the remainder of 2014.

"We are happy to report that the initial feedback on Dario from our distribution partners in the field has been positive, and we are looking forward to sharing some early details with our investors as well as to review our goals for the rest of the year and our plans to achieve them," said Mr. Raphael.

Participants should call one of the numbers listed below and provide the confirmation code 6229537.

National free phone - United States of America:

1 877 280 1254

National free phone - United Kingdom:

0800 279 5004

Local - Tel Aviv, Israel:

03 721 9510


+44 (0) 20 3427 1903

An archive of the webcast will be available approximately one hour after completion of the live event and will be accessible on the Investor Relations section of LabStyle's website at for 30 days.

About LabStyle Innovations

LabStyle Innovations Corp. (OTCQB:DRIO) develops and commercializes patent-pending technology providing consumers with laboratory-testing capabilities using smart mobile devices. LabStyle's flagship product is the Dario personalized smart meter. Dario received CE mark certification in September 2013 and began a world rollout in select countries in December 2013. LabStyle filed a Premarket Notification Application, also known as a 510(k), with the US Food and Drug Administration (FDA) for the Dario smart meter (Dario Blood Glucose Monitoring System) in December 2013. LabStyle is pursuing patent applications in multiple areas covering the specific processes related to blood glucose level measurement as well as more general methods of rapid tests of body fluids using mobile devices and cloud-based services. For more information: and

Cautionary Note Regarding Forward-Looking Statements

This news release, the investor conference call referred to herein, and the statements of representatives and partners of LabStyle Innovations Corp. (the "Company") related thereto contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.



Investor Relations

Brenda Zeitlin

Booke and Company Inc.

LabStyle Innovations

1 212 490 9095

972 54 3304831


Help employers find you! Check out all the jobs and post your resume.

Back to news